Neogenomics (NEO) Payables (2010 - 2026)

Neogenomics (NEO) has 17 years of Payables data on file, last reported at $21.0 million in Q2 2026.

• Quarterly Payables fell 23.79% year-over-year to $21.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $21.0 million (down 23.79% YoY) and the FY2025 annual result came in at $23.1 million, down 89.62% from the prior year.
• Payables fell to $21.0 million in Q2 2026, from $25.9 million in the prior quarter.
• In the past five years, Payables ranged from a high of $222.4 million in Q4 2024 to a low of $13.7 million in Q3 2022.
• A 5-year average of $64.5 million and a median of $21.8 million in 2025 frame the typical range for Payables.
• Annual changes were most pronounced in 2024 — Payables surged 1189.84% — and 2025, when it plunged 89.62%.
• Tracing NEO's Payables over 5 years: stood at $20.5 million in 2022, then decreased by 0.86% to $20.3 million in 2023, then jumped by 993.66% to $222.4 million in 2024, then sank by 89.62% to $23.1 million in 2025, then decreased by 9.26% to $21.0 million in 2026.
• The last three Payables figures came in at $21.0 million (Q2 2026), $25.9 million (Q1 2026), and $23.1 million (Q4 2025), per Business Quant data.